A small biotech company faced significant challenges expressing and purifying a complex protein, which was only producible as inclusion bodies (IBs) in E. coli. With limited data on the protein’s mechanism or mode of action, they required a partner to drive development.
A very early-stage biotech company with limited funding needed to build a solid data package to attract investor interest. While initial protein expression had been done, a properly cell line and scalable process were essential for moving forward.
An established virtual biotech with a growing pipeline needed an agile R&D partner to provide wet-lab capabilities and scientific expertise. Without in-house labs, they relied on Bioneer for flexible, on-demand development support across multiple programs.
A small biotech struggled with product instability during manufacturing at a large CMO, which couldn't establish a suitable buffer exchange for lyophilization. Bioneer quickly developed and implemented a TFF process, enabling successful stabilization, lyophilization, and fill-finish.
Architectural organization and molecular profiling of 3D cancer heterospheroids and their application in drug testing Authors: Boye Schnack Nielsen, Natasha Helleberg Madsen, Jesper Larsen, Isabella Skandorff , Monika Gad and Kim Holmstrøm. Published in Frontiers in Oncology Abstract 3D cancer cell cultures have enabled new opportunities for replacing compound testing in experimental animals. However, [...]
DigitSTEM – a new, large Danish stem cell research initiative in the neurodegenerative and immuno-oncology fields. DigitSTEM is a four-year stem cell focused research collaboration between The Technical University of Denmark (DTU), University of Copenhagen and Bioneer A/S. The collaborating partners are: DTU Bioengineering, DTU Compute and DTU Health Tech, The Novo Nordisk Foundation [...]
Bioneer A/S announces a strategic collaboration with the National Biologics Facility (NBF) to commercialize their combined CRO services for mammalian expression of recombinant proteins. Copenhagen, September 16th, 2021. Bioneer A/S, a globally operating Danish specialty-CRO creating and commercializing innovative research service solutions for early stage drug development and in vitro modelling, announced today [...]
Bioneer is happy to announce that we will be participating in the Rare Diseases training course: Pluripotent stem cells for rare disease research: banking, data, application from October 25th to 27th in an online format. Rare disease (RD) is one area where national and international multidisciplinary collaborations are valuable to overcome some of [...]
Bioneer is delighted to participate to the 23rd Symposium "Signal Transduction at the Blood-Brain Barriers", held September 22-24, 2021, as a virtual symposium. The 23rd International Symposium "Signal Transduction at the Blood-Brain Barriers" was originally planned for September 2021 in Bari / Italy, but had to be postponed to September/October 2022. The Scientific [...]
Gluten Degradation, Pharmacokinetics, Safety, and Tolerability of TAK-062, an Engineered Enzyme to Treat Celiac Disease Authors: Ingrid Swanson Pultz (PvP Biologics, Inc), Malcolm Hill (PvP Biologics, Inc), Joanne M. Vitanza (PvP Biologics, Inc), Clancey Wolf (PvP Biologics, Inc), Lasse Saaby (Bioneer A/S), Tina Liu (Takeda Pharmaceuticals International Co), Peter Winkle (Anaheim Clinical Trials), Daniel [...]
